Travere Therapeutics Income Statement (2011-2026) | TVTX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	54.62M	55.00M		23.41M	28.63M	28.07M	29.34M	30.89M	32.20M	37.09M	45.06M	41.37M	54.12M	62.90M	74.79M	81.73M	114.45M	40.00M	129.69M	127.20M
Cost of Revenue (Quarter)	1.65M	1.59M	-1.07M	2.14M	2.05M	1.11M	0.87M	4.14M	1.45M	1.29M	4.56M	1.50M	2.06M	1.63M	2.55M	4.68M	1.52M	1.58M	2.55M	24.82M
Gross Profit (Quarter)	52.97M	53.41M		21.27M	26.58M	26.96M	28.47M	26.74M	30.74M	35.81M	40.49M	39.87M	52.05M	61.27M	72.23M	77.05M	112.93M	38.41M	127.14M	102.38M
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)	51.81M	48.41M	53.00M	56.61M	59.68M	57.15M	58.09M	58.16M	66.49M	60.59M	59.75M	49.42M	54.33M	51.68M	62.07M	46.89M	49.36M	51.89M	57.87M	57.09M
Selling, General & Administrative (Quarter)	34.97M	36.06M	18.48M	46.79M	52.98M	52.42M	57.09M	65.95M	68.20M	67.80M	63.59M	64.22M	64.78M	65.62M	69.50M	72.84M	76.22M	86.45M	101.69M	80.25M
Restructuring Costs (Quarter)											11.39M	0.26M	0.65M	0.12M	1.40M
Other Operating Expenses (Quarter)	3.16M	15.46M	-25.03M	-8.01M	-5.50M	1.11M	0.87M	4.14M	1.45M	1.29M	4.56M	66.71M	2.06M	1.63M	2.55M	4.68M	1.52M	1.58M	2.55M	26.77M
Operating Expenses (Quarter)	89.93M	99.93M	46.45M	95.39M	107.16M	110.68M	116.04M	128.26M	136.15M	129.68M	139.29M	180.61M	121.82M	119.05M	135.52M	124.41M	127.10M	139.93M	162.12M	164.11M
Operating Income (Quarter)	-35.31M	-31.71M	-84.85M	-71.98M	-78.53M	-82.60M	-86.70M	-97.37M	-103.95M	-92.58M	-94.23M	-139.24M	-67.70M	-56.15M	-60.74M	-42.67M	-12.65M	24.93M	-32.43M	-36.91M
EBIT (Quarter)	-35.31M	-31.71M	-84.85M	-71.98M	-78.53M	-82.60M	-86.70M	-97.37M	-103.95M	-92.58M	-94.23M	-139.24M	-67.70M	-56.15M	-60.74M	-42.67M	-12.65M	24.93M	-32.43M	-36.91M
Non-operating items
Interest & Investment Income (Quarter)	-4.85M	-4.90M	-4.61M	0.28M	0.78M	-2.83M	3.12M	-2.85M	5.13M	5.84M	7.15M	6.03M	4.42M	3.57M	3.79M	3.79M	3.29M	3.05M	2.59M	2.58M
Other Non Operating Income (Quarter)	0.22M	0.65M	-1.09M	-7.60M			8.55M	0.09M	-0.20M	0.34M	1.37M	0.24M	-3.50M	0.52M	-0.58M	0.55M	-0.53M	0.49M	11.07M	-0.09M
Non Operating Income (Quarter)	0.22M	0.65M	-17.23M	0.03M	0.66M	-0.59M	0.87M	0.88M	2.08M	3.36M	-4.73M	3.47M	-1.86M	0.52M	-0.58M	1.49M	-0.53M	0.49M	11.07M	-0.09M
Net income details
EBT (Quarter)	-38.96M	-35.60M	-88.77M	-81.69M	-79.97M	-83.92M	-85.57M	-96.49M	-101.87M	-89.23M	-88.53M	-135.77M	-69.57M	-54.84M	-60.34M	-41.19M	-12.73M	25.71M	-21.07M	-36.72M
Tax Provisions (Quarter)	0.05M	0.04M	0.00M	0.05M	0.05M	0.14M	0.06M	0.08M	0.07M	0.01M	0.07M	0.19M	0.09M	-0.08M	-0.07M	0.04M	0.02M	0.01M	0.92M	-0.12M
Profit After Tax (Quarter)	-39.01M	-35.64M	-88.77M	-81.75M	-80.02M	-69.66M	-65.82M	-86.33M	-101.93M	-89.24M	-88.60M	-136.06M	-70.41M	-54.75M	-61.18M	-41.23M	-12.76M	25.71M	2.73M	-37.10M
Income from Continuing Operations (Quarter)	-39.01M	-35.64M	-88.77M	-81.75M	-80.02M	-84.06M	-85.64M	-96.56M	-101.93M	-89.24M	-88.60M	-135.96M	-69.65M	-54.75M	-60.27M	-41.23M	-12.76M	25.71M	-21.99M	-36.60M
Consolidated Net Income (Quarter)	-39.01M	-35.64M	-88.77M	5.78M	12.99M	14.41M	19.81M	10.23M	16.30M	239.98M	-1.58M	-0.10M	-0.76M	-0.06M	0.00M				24.71M	-0.50M
Income towards Parent Company (Quarter)	-39.01M	-35.64M	-88.77M	5.78M	12.99M	14.41M	19.81M	10.23M	16.30M	239.98M	-1.58M	-0.10M	-0.76M	-0.06M	0.00M				24.71M	-0.50M
Net Income towards Common Stockholders (Quarter)	-39.01M	-35.64M	-88.77M	5.78M	12.99M	14.41M	19.81M	10.23M	16.30M	239.98M	-1.58M	-0.10M	-0.76M	-0.06M	0.00M				24.71M	-0.50M
Additional items
EPS (Basic) (Quarter)	-0.64	-0.59	-1.46	-1.29	-1.25	-1.09	-1.03	-1.42	-1.34	-1.17	-1.16	-1.76	-0.91	-0.70	-0.70	-0.47	-0.14	0.29	0.03	-0.40
EPS (Weighted Average and Diluted) (Quarter)	-0.64	-0.59	-1.46	-1.29	-1.25	-1.31	-1.03	-1.42	-1.13	-1.17	-1.16	-1.76	-0.91	-0.70	-0.71	-0.47	-0.14	0.28	-0.25	-0.40
Shares Outstanding (Weighted Average) (Quarter)	58.43M	60.80M	59.83M	63.13M	63.39M	63.60M	63.76M	68.17M	72.11M	73.52M	74.27M	77.14M	77.32M	77.47M	78.89M	88.36M	88.95M	89.23M	89.21M	91.87M
Shares Outstanding (Diluted Average) (Quarter)	60.57M	59.23M	59.83M	63.13M	63.64M	63.60M	63.76M	68.17M	72.11M	76.31M	74.27M	77.14M	77.50M	77.47M	78.89M	88.36M	88.65M	102.62M	89.21M	91.87M
EBITDA (Quarter)	-39.39M	-35.52M	-51.61M	-77.10M	-66.42M	-68.27M	-69.03M	-85.60M	-87.31M	150.94M	-87.98M	-136.50M	-70.15M	-54.19M	-59.33M	-41.99M	-12.72M	25.46M	2.59M	-36.98M
Interest Expenses (Quarter)									2.80M	2.82M	2.83M	2.80M	2.79M	2.78M	2.83M	2.90M	2.85M	2.75M	2.20M	2.30M
Tax Rate (Quarter)	-0.13%	-0.12%	0.00%	-0.06%	-0.07%	-0.17%	-0.07%	-0.08%	-0.06%	-0.01%	-0.08%	-0.14%	-0.12%	0.15%	0.12%	-0.09%	-0.16%	0.03%	-4.37%	0.33%

Research Tools

Travere Therapeutics Income Statement (2011-2026) | TVTX

Create an account

Sign In

Reset Password